ClinicalTrials.gg
RecruitingNCT07033715Updated Jun 24, 2025

Exercise in Hereditary ATTR (ATTRv) Amyloidosis

An interventional study of Exercise in Amyloidosis, Hereditary, Transthyretin-Related, sponsored by University of Maia. Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by University of Maia · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Oct 2024, registered Apr 2025).
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Portugal — 7 open to participants now, 9 under way, 4 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · Portugal.

Planned enrollment
9th of 10
42 · median 474
Started
2024
with 1 other
No phase
Only one
of the 15
Registered
14th of 15
by date
Lead sponsor
1 of 15
University of Maia

Among the 15 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Portugal, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is the only one with no phase, and was the 14th registered.

Amyloidosis, Hereditary, Transthyretin-Related

82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.

Browse Amyloidosis, Hereditary, Transthyretin-Related studies →

Open to participants now

7 of the 15 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Portugal are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in Portugal, or all of them as a file.
02

Study summary

This study aims to explore the effects of a 12-week exercise intervention on the physical and mental health of people living with Hereditary ATTR (ATTRv) Amyloidosis, a rare genetic disease caused by mutations in the transthyretin gene, leading to the deposition of amyloid fibrils in nerves and organs.

Read the detailed description

Considering that few studies to date have explored the effects of exercise in ATTRv Amyloidosis, this study aims to increase the existing evidence in this under-researched area. Besides, the existing research was performed with liver transplanted patients and focused exclusively on physical fitness outcomes. Therefore, we aim to include those patients who are currently receiving new therapies and extend research to the mental benefits of exercising, questioning whether exercise can ease the mental burden of living with such a debilitating disease. This research also seeks to raise awareness among patients and healthcare professionals about the importance of an active lifestyle in improving HRQoL in this community.

03

Conditions studied

  • Amyloidosis, Hereditary, Transthyretin-Related

Keywords

  • ATTRv
  • exercise
  • physical fitness
  • mental health
  • HRQoL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ATTRv Amyloidosis patients living in Portugal;
  • Disease stage 1 or 2;
  • No medical for exercising;
  • Ability to provide .

Exclusion criteria

Exclusion Criteria:

- Having undergone a liver transplant in the past 6 months.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Exercise

    Participants will be enrolled in a 12-week supervised exercise intervention.

    Other: Exercise

  • No intervention
    Control

    Participants will not be enrolled in the 12-week exercise program.

Interventions

  • OtherExercise

    The exercise sessions will have a frequency of 3 times a week and a duration of 60 minutes per session. Exercise intensity will be gradually increased throughout the program and will be monitored every session using Borg's Rated Perceived Exertion scale, aiming at levels of 12-13 ("fairly light to somewhat hard"). The program will be mainly composed of cardiorespiratory exercises and resistance exercises. It will also comprise flexibility exercises to improve joint range of motion and neuromotor exercises involving motor skills (balance, agility, coordination, gait...), proprioceptive training and multifaceted activities (tai ji, yoga...).

06

What researchers measure

Primary outcomes

  1. Strength of the knee extensors

    The strength of the knee extensors (N) will be assessed with a handheld strength device (DynaMo, VALD Performance).

    Time frame: Strength of the knee extensors will be assessed at baseline and immediately after the 12-week exercise intervention.

  2. Grip strength

    Grip strength (N) will be assessed with a handheld strength device (DynaMo, VALD Performance).

    Time frame: Grip strength will be assessed at baseline and immediately after the 12-week exercise intervention.

  3. Walking capacity

    Walking capacity will be assessed with the 6-minute walk test, registering the total distance covered in the test (m).

    Time frame: Walking capacity will be assessed at baseline and immediately after the 12-week exercise intervention.

  4. Body mass index

    Body mass index (kg/m\^2) will be calculated from the ratio between weight and the square of height.

    Time frame: Body mass index will be assessed at baseline and immediately after the 12-week exercise intervention.

  5. Weight

    Weight (kg) will be assessed with a bioelectrical impedance device (TANITA BC-545N).

    Time frame: Weight will be assessed at baseline and immediatly after the 12-week exercise intervention.

  6. Fat free mass

    Fat free mass (kg) will be assessed with a bioelectrical impedance device (TANITA BC-545N).

    Time frame: Fat free mass will be assessed at baseline and immediately after the 12-week exercise intervention.

  7. Fat mass

    Fat mass (%) will be assessed with a bioelectrical impedance device (TANITA BC-545N).

    Time frame: Fat mass will be assessed at baseline and immediately after the 12-week exercise intervention.

  8. Body water

    Body water (kg) will be assessed with a bioelectrical impedance device (TANITA BC-545N).

    Time frame: Body water will be assessed at baseline and immediately after the 12-week exercise intervention.

Secondary outcomes

  1. Mental health

    Mental health will be evaluated using the Portuguese adaptation of the Mental Health Continuum-Short Form (MHC-SF), a mental-health questionnaire with 14 items that investigates respondent's emotional (3 items), social (5 items) and psychological (6 items) well-being. Each item is rated on a 6-point Likert scale, ranging from 0 (never) to 5 (everyday).

    Time frame: Mental health will be assessed at baseline and immediately after the 12-week exercise intervention.

Other outcomes

  1. Health-related quality of life (HRQoL)

    To assess HRQoL, the EQ-5D-3L will be used to determine patients' health state in 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2) and extreme problems (3).

    Time frame: HRQoL will be assessed at baseline and immediately after the 12-week exercise intervention.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The study will involve the collection of sensitive personal data regarding patient's physical and mental health.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Sep 2025, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2025
First posted
Jun 24, 2025
StartActual
Oct 1, 2024
Primary completionEst.
Sep 30, 2025
CompletionEst.
Sep 30, 2026
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07033715
Lead sponsor
University of Maia
Responsible party
Cláudia Barata (Principal Investigator, University of Maia) — Principal investigator
First posted
Jun 24, 2025
Start date
Oct 1, 2024
Primary completion
Sep 30, 2025 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Jun 24, 2025

Study contacts

Cláudia F. Barata, PhD
Contact
claudiapfb19@gmail.com
+351915381161
João L. Viana, PhD
Contact
D011290@umaia.pt
João L. Viana, PhD
study director · University of Maia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion